Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes

84 Citationer (Scopus)

Abstract

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) labels warn about acute pancreatitis (AP) and impose doctors to inform patients about symptoms of AP. Here we systematically reviewed the risk of AP in randomized placebo-controlled trials (RCTs) investigating the effect of GLP-1RAs in type 2 diabetes. We performed a systematic review with meta-analysis of long-term (minimum 24 months), placebo-controlled GLP-1RA RCTs in which AP was a predefined adverse event and adjudicated by blinded and independent adjudicating committees. Three high-quality RCTs included a total of 9,347 GLP-1RA-treated and 9,353 placebo-treated patients with type 2 diabetes. Compared to placebo, treatment with GLP1-RA was not associated with increased risk of AP (Peto odds ratio 0.745 [95% CI 0.47-1.17]). Trial Sequential Analysis suggested that additional evidence is needed. In conclusion, this review found no evidence that treatment with GLP-1RA increase the risk of AP in patients with type 2 diabetes.

OriginalsprogEngelsk
TidsskriftDiabetes, Obesity and Metabolism
Vol/bind19
Udgave nummer6
Sider (fra-til)906-908
ISSN1462-8902
DOI
StatusUdgivet - 1 jun. 2017

Fingeraftryk

Dyk ned i forskningsemnerne om 'Glucagon-Like Peptide-1 Agonists and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes'. Sammen danner de et unikt fingeraftryk.

Citationsformater